Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,585 signal articles · 321 in last 24h · 112,405 total before filter · latest 1h ago
321last 24h
2134last 7d
379● bullish (7d)
186● bearish (7d)
204publishers
AllMacro296Earnings1213M&A90Regulatory23Product13Analyst20
✕ clear all filtersticker: HIMSSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations
24/7 Wall St.91d agobearish
BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations

Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a Neutral rating. The firm called the recent results “a mixed quarter” and argued that the bar needs to come down before HIMS stock can work again. The ... BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations

JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story
24/7 Wall St.92d agobearish
JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story

Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target to $33 from $35 while reaffirming an Overweight rating, characterizing results as mixed and updating the 2026 outlook to reflect the strategic shift ... JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story